Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARK7 | Q99497 | 5/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
| ▸ | DAO | P14920 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.44 |
| ▸ | CASR | P41180 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.44 |
| ▸ | GSK3A | P49840 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | MGLL | Q99685 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15437827 | 0.85 | NR1H2 (0.52) | SMN1; SMN2ALDH1A1HTT | |
| SCHEMBL15437985 | 0.84 | CASP3 (0.59) | PARK7SMN1; SMN2ALDH1A1MAPTKDM4E | |
| SCHEMBL15437849 | 0.83 | MAPT (0.53) | PARK7SMN1; SMN2ALDH1A1MAPTKDM4E | |
| SCHEMBL7954623 | 0.83 | CASP3 (0.59) | PARK7SLC6A3DAOSMN1; SMN2ALDH1A1 | |
| SCHEMBL6310937 | 0.75 | LCK (0.57) | SMN1; SMN2MAPTRAB9ACASP3HTT | |
| SCHEMBL17260677 | 0.75 | TDP1 (0.60) | SLC6A3SMN1; SMN2ALDH1A1CASP3 | |
| SCHEMBL28080838 | 0.74 | GSK3A (0.61) | SMN1; SMN2ALDH1A1MAPTKDM4EGAA | |
| SCHEMBL15438146 | 0.74 | LCK (0.48) | DAOALDH1A1TAAR1 | |
| SCHEMBL16301946 | 0.74 | CASP3 (0.47) | PARK7DAOSMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL28080827 | 0.73 | TDP1 (0.68) | ALDH1A1CASP3GSK3AGSK3BMGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9296690-B2 | Method for inhibiting differentiation of osteoclast and pharmaceutical composition comprising thereof | METACINE, INC. (KR) | 2016-03-29 | — | — | US | claimed |
| US-20140275203-A1 | Method for Inhibiting Differentiation of Osteoclast and Pharmaceutical Composition Comprising Thereof | METACINE, INC. (KR) | 2014-09-18 | — | — | US | claimed |
| US-20140031563-A1 | New compounds for inhibiting differentiation of osteoclast and pharmaceutical composition comprising thereof | METACINE, INC. (KR) | 2014-01-30 | — | — | US | claimed |
| US-9296690-B2 | Method for inhibiting differentiation of osteoclast and pharmaceutical composition comprising thereof | METACINE, INC. (KR) | 2016-03-29 | — | — | US | disclosed |
| US-9296690-B2 | Method for inhibiting differentiation of osteoclast and pharmaceutical composition comprising thereof | METACINE, INC. (KR) | 2016-03-29 | — | — | US | disclosed |
| US-9296690-B2 | Method for inhibiting differentiation of osteoclast and pharmaceutical composition comprising thereof | METACINE, INC. (KR) | 2016-03-29 | — | — | US | disclosed |
| US-20140275203-A1 | Method for Inhibiting Differentiation of Osteoclast and Pharmaceutical Composition Comprising Thereof | METACINE, INC. (KR) | 2014-09-18 | — | — | US | disclosed |
| US-20140275203-A1 | Method for Inhibiting Differentiation of Osteoclast and Pharmaceutical Composition Comprising Thereof | METACINE, INC. (KR) | 2014-09-18 | — | — | US | disclosed |
| US-20140275203-A1 | Method for Inhibiting Differentiation of Osteoclast and Pharmaceutical Composition Comprising Thereof | METACINE, INC. (KR) | 2014-09-18 | — | — | US | disclosed |
| US-20140031563-A1 | New compounds for inhibiting differentiation of osteoclast and pharmaceutical composition comprising thereof | METACINE, INC. (KR) | 2014-01-30 | — | — | US | disclosed |
| US-20140031563-A1 | New compounds for inhibiting differentiation of osteoclast and pharmaceutical composition comprising thereof | METACINE, INC. (KR) | 2014-01-30 | — | — | US | disclosed |
| US-20140031563-A1 | New compounds for inhibiting differentiation of osteoclast and pharmaceutical composition comprising thereof | METACINE, INC. (KR) | 2014-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140031563-A1 | New compounds for inhibiting differentiation of osteoclast and pharmaceutical composition comprising thereof | SOST, MYD88, MSR1 | PARK7 3417/4885SLC6A3 4166/4885DAO 4142/4885 |
| US-20140275203-A1 | Method for Inhibiting Differentiation of Osteoclast and Pharmaceutical Composition Comprising Thereof | SOST, MYD88, MSR1 | PARK7 2869/4885SLC6A3 3104/4885DAO 4051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.